What changed: Neuroendocrine tumours
Every dated change on the records linked to Neuroendocrine tumours, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
August 2026 · 1
2026 · 2
- 2026GuidelineNeuroendocrine tumoursGuideline NCCN 2026 / ENETS 2023: Diagnosis and staging
Histology with Ki-67 grading; 68Ga/64Cu-DOTATATE PET/CT ± FDG PET; triple-phase CT or MRI of the liver; chromogranin A and syndrome-specific hormones; germline testing for pancreatic NETs and paragangliomas. (NCCN Neuroendocrine and Adrenal Tumors)
- 2026Milestone177Lu-edotreotideFDA accepts 177Lu-edotreotide NDA (PDUFA 28 August); ACTION-1 dosimetry published; pancreatic subgroup of COMPETE at ENETS
A milestone in how this cancer is treated.
March 2025 · 1
2025 · 4
- 2025ApprovalCabozantinibCabozantinib approved in US
Advanced pancreatic and extra-pancreatic neuroendocrine tumours after prior therapy (CABINET)
- 2025Trial resultALPHAMEDIX-02ALPHAMEDIX-02 reported
ORR 54.
- 2025Trial resultCOMPETECOMPETE reported
PFS 23.
- 2025MilestoneCabozantinibCabozantinib approved (March); COMPETE positive (ENETS, Lancet); AlphaMedix phase 2 meets all endpoints (October)
A milestone in how this cancer is treated.
June 2024 · 1
April 2024 · 1
2024 · 4
- 2024ApprovalLutetium-177 dotatateLutetium-177 dotatate approved in US
Paediatric ≥12 years; first-line (NETTER-2 label)
- 2024Trial resultCABINET (Alliance A021602)CABINET (Alliance A021602) reported
PFS HR 0.
- 2024MilestoneNeuroendocrine tumoursNETTER-2: first-line PRRT
A milestone in how this cancer is treated.
- 2024MilestoneLutetium-177 dotatateNETTER-2: PRRT first line in grade 2-3; CABINET published; AlphaMedix Breakthrough designation
A milestone in how this cancer is treated.
2020 · 5
- 2020ApprovalGallium-68 DOTATATE (and Cu-64 DOTATATE)Gallium-68 DOTATATE (and Cu-64 DOTATATE) approved in US
Same (Cu-64 DOTATATE)
- 2020ApprovalSurufatinibSurufatinib approved in CN
Advanced non-pancreatic neuroendocrine tumours; pancreatic neuroendocrine tumours from 2021
- 2020Trial resultDART (SWOG S1609): nivolumab plus ipilimumab in rare tumoursDART (SWOG S1609): nivolumab plus ipilimumab in rare tumours reported
Neuroendocrine cohort: about one in four responded, concentrated in high-grade disease; angiosarcoma cohort about one in four, mostly cutaneous scalp and face tumours; many other cohorts inactive.
- 2020Trial resultSANET-ep and SANET-pSANET-ep and SANET-p reported
PFS HR 0.
- 2020MilestoneSANET-ep and SANET-pSANET trials positive in China (surufatinib)
A milestone in how this cancer is treated.
January 2018 · 1
2018 · 4
- 2018ApprovalIobenguane I-131 (therapeutic)Iobenguane I-131 (therapeutic) approved in US
Iobenguane scan-positive unresectable, locally advanced or metastatic phaeochromocytoma or paraganglioma in patients 12 and older (discontinued 2024)
- 2018ApprovalLutetium-177 dotatateLutetium-177 dotatate approved in US
SSTR+ GEP-NETs
- 2018MilestoneLutetium-177 dotatateLutathera approved
A milestone in how this cancer is treated.
- 2018MilestoneLutetium-177 dotatateLutathera approved (NETTER-1): PRRT enters standard care
A milestone in how this cancer is treated.
September 2017 · 1
2017 · 5
- 2017ApprovalGallium-68 DOTATATE (and Cu-64 DOTATATE)Gallium-68 DOTATATE (and Cu-64 DOTATATE) approved in EU
SomaKit TOC (Ga-68 DOTATOC)
- 2017ApprovalLutetium-177 dotatateLutetium-177 dotatate approved in EU
First approval globally (Sep 2017)
- 2017ApprovalTelotristat ethylTelotristat ethyl approved in EU
Same (Xermelo)
- 2017ApprovalTelotristat ethylTelotristat ethyl approved in US
Carcinoid syndrome diarrhoea with somatostatin analogue therapy in adults inadequately controlled by SSA alone
- 2017Trial resultNETTER-1NETTER-1 reported
PFS at 20 months 65.
2016 · 2
- 2016ApprovalGallium-68 DOTATATE (and Cu-64 DOTATATE)Gallium-68 DOTATATE (and Cu-64 DOTATATE) approved in US
PET localisation of SSTR-positive neuroendocrine tumours (Ga-68 DOTATATE)
- 2016MilestoneSomatostatin receptor PET (68Ga/64Cu-DOTATATE)68Ga-DOTATATE PET (Netspot) approved; RADIANT-4 extends everolimus to lung/GI NETs
A milestone in how this cancer is treated.
2014 · 3
- 2014ApprovalSomatostatin analogues (octreotide, lanreotide)Somatostatin analogues (octreotide, lanreotide) approved in US
Unresectable GEP-NETs to improve PFS (lanreotide)
- 2014Trial resultCLARINETCLARINET reported
PFS HR 0.
- 2014MilestoneCLARINETCLARINET: lanreotide antiproliferative approval
A milestone in how this cancer is treated.
2011 · 2
2009 · 2
2000 · 1
1994 · 1
1988 · 2
- 1988ApprovalSomatostatin analogues (octreotide, lanreotide)Somatostatin analogues (octreotide, lanreotide) approved in US
Carcinoid syndrome symptoms (octreotide)
- 1988MilestoneSomatostatin analogues (octreotide, lanreotide)Octreotide approved for carcinoid syndrome
A milestone in how this cancer is treated.